Study Evaluating Prevenar in High-Risk Children

Prospective Post-Marketing Surveillance Study of Prevenar in High-Risk Children Aged 2 to 5 Years

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00234338

Enrollment

5000

Registered

2005-10-06

Start date

2005-10-31

Completion date

2007-04-30

Last updated

2007-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumococcal Disease

Keywords

Children, Vaccine, Prevenar

Brief summary

The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

2 Years to 5 Years

Healthy volunteers

Yes

Inclusion criteria

* High-risk children ages 2 to 5 years old

Exclusion criteria

* Prior administration of Prevenar * Prior and/or concurrent administration of 23 vPs vaccine

Countries

Germany

Outcome results